Psilocybin-Research.com
Research. Clarity. Progress.
Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.
| Source | Count | Share | Status |
|---|---|---|---|
| Europe PMC | 2,654 | 69.6% | Active |
| PubMed | 309 | 8.1% | Active |
| ClinicalTrials.gov | 287 | 7.5% | Active |
| PsyArXiv | 218 | 5.7% | Active |
| Crossref | 168 | 4.4% | Active |
| bioRxiv | 142 | 3.7% | Active |
| medRxiv | 34 | 0.9% | Active |
Most recently published records currently stored in SQLite.
Neuropsychopharmacology Reports · 2026-08-31
The Brown University Psychopharmacology Update · 2026-07-31
Journal of Drug Issues · 2026-06-30
ClinicalTrials.gov · 2026-06-30
The Brown University Psychopharmacology Update · 2026-06-30
The Brown University Psychopharmacology Update · 2026-06-30
Journal of Affective Disorders Reports · 2026-06-30
Palliative medicine · 2026-06-30
Physical chemistry chemical physics: PCCP · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
Background: Depression is a major global health challenge, affecting over 300 million people worldwide. Current pharmacological and psychotherapeutic interventions have limited efficacy, underscoring the need for novel approaches. Emerging evidence suggests that peak emotional experiences characterized by awe, transcendence, and meaning hold promise for rapi...
Abstract Background: Body Image Disturbance (BID) is the distorted experience of one’s body. BID presents a risk for the onset, maintenance and relapse of body dysmorphic disorder and eating disorders, including anorexia nervosa (AN). Current treatments tend to focus on the cognitive and behavioural aspects while overlooking the perceptual symptoms and BID f...
Abstract Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or “full spectrum” (psychedelic) mushroom extract (PME), may differ from those of chemically synthesiz...
Abstract Background Psilocybin-containing mushrooms induce antidepressant and momentary increase in blood pressure (BP) with potential risk to users with cardiovascular diseases. Irregularities in nitric oxide (NO) levels play a key role in endothelial dysfunctions leading to increases in BP. Mushrooms species show large variation in potency which may potent...
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the invo...
Abstract Psilocybin is the psychoactive substance contained in the psilocybe(hallucinogenic) mushroom, which has received considerable attention among the scientific community in recent years. Human studies have demonstrated that even a single-dose of psilocybin can improve debilitating physical and psychological symptoms with durable long-term effects. >136...
Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient had failed to respond to conventional psychotherapeutic treatment. After three sessions of psilocybin-assisted psychotherapy, the patient experienced a reduction in anxiety and fear associated with closed spaces, elevators,...
Abstract Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here we leveraged the differential outcome in responders and non-responders to psilocybin (10mg and 25mg, 7 days apart) therapy for depression - to gain new insights into regions and networks implicated in the restoration of h...
Abstract Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble-burying, suggest that psilocybin may be effective in treating obsessive-compulsive disorder. On this background, we set out to explore 1) the role of 5-HT2A and 5-HT1A receptors in the effect of psilocybin on marble-burying; 2) the effect of...
Abstract Psilocybin is a psychedelic substance approaching clinical use. The drug has long-lasting effects after single or multiple administrations and enhances structural plasticity in the brain. Little is known if the plasticity inducing effects of psilocybin could be timed to other treatments and promote a larger effect. We investigated the effect of psil...